PubMed

The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.

PKC-DRS Study Group.

Diabetes. 2005 Jul;54(7):2188-97.PMID: 15983221 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.

PKC-DRS2 Group, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.

Ophthalmology. 2006 Dec;113(12):2221-30. Epub 2006 Sep 20.PMID: 16989901 [PubMed - indexed for MEDLINE]Related articles

Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.

PKC-DMES Study Group.

Arch Ophthalmol. 2007 Mar;125(3):318-24.PMID: 17353401 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.

Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L; PKC-DRS2 Study Group.

Invest Ophthalmol Vis Sci. 2009 Jan;50(1):1-4. Epub 2008 Aug 15.PMID: 18708615 [PubMed - indexed for MEDLINE]Related articles

Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.

Strøm C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M.

Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3855-8.PMID: 16186374 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.

Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ 3rd; MBBQ Study Group.

Clin Ther. 2005 Aug;27(8):1164-80.PMID: 16199243 [PubMed - indexed for MEDLINE]Related articles

Ruboxistaurin: LY 333531.

[No authors listed]

Drugs R D. 2007;8(3):193-9. Review.PMID: 17472415 [PubMed - indexed for MEDLINE]Related articles

Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.

Girach A, Aiello LP, Milton RC, Davis MD, Danis RP, Zhi X, Sheetz MJ, Vignati L; PKC-DRS2 Study Group.

Eye (Lond). 2009 Jan;23(1):209-14. Epub 2008 Nov 7.PMID: 18989348 [PubMed - indexed for MEDLINE]Related articles

Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.

Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE.

Invest Ophthalmol Vis Sci. 2006 Jan;47(1):86-92.PMID: 16384948 [PubMed - indexed for MEDLINE]Related articlesFree article

A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.

Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ 3rd, Wolka AM, Vinik AI.

Diabetes Care. 2007 Apr;30(4):896-902.PMID: 17392551 [PubMed - indexed for MEDLINE]Related articlesFree article

Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease.

Tuttle KR, McGill JB, Haney DJ, Lin TE, Anderson PW; PKC-DRS, PKC-DMES, and PKC-DRS 2 Study Groups.

Clin J Am Soc Nephrol. 2007 Jul;2(4):631-6. Epub 2007 May 30.PMID: 17699475 [PubMed - indexed for MEDLINE]Related articlesFree article

Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.

Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK.

J Diabetes Complications. 2008 Mar-Apr;22(2):88-95.PMID: 18280438 [PubMed - indexed for MEDLINE]Related articles

Ruboxistaurin mesilate hydrate for diabetic retinopathy.

Schwartz SG, Flynn HW Jr, Aiello LP.

Drugs Today (Barc). 2009 Apr;45(4):269-74. Review.PMID: 19499092 [PubMed - indexed for MEDLINE]Related articles

Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25.

Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, Williams GA, Ferris FL 3rd.

Arch Ophthalmol. 1999 Dec;117(12):1600-6.PMID: 10604663 [PubMed - indexed for MEDLINE]Related articles

The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study.

Chew EY, Ferris FL 3rd, Csaky KG, Murphy RP, Agrón E, Thompson DJ, Reed GF, Schachat AP.

Ophthalmology. 2003 Sep;110(9):1683-9.PMID: 13129862 [PubMed - indexed for MEDLINE]Related articles

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.

McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL.

Expert Opin Drug Saf. 2006 Nov;5(6):835-45. Review.PMID: 17044810 [PubMed - indexed for MEDLINE]Related articles

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.

[No authors listed]

Ophthalmology. 1991 May;98(5 Suppl):766-85.PMID: 2062512 [PubMed - indexed for MEDLINE]Related articles

The potential role of PKC beta in diabetic retinopathy and macular edema.

Aiello LP.

Surv Ophthalmol. 2002 Dec;47 Suppl 2:S263-9. Review.PMID: 12507628 [PubMed - indexed for MEDLINE]Related articles

Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.

Frank RN.

Am J Ophthalmol. 2002 May;133(5):693-8. Review.PMID: 11992868 [PubMed - indexed for MEDLINE]Related articles

Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group.

Fong DS, Ferris FL 3rd, Davis MD, Chew EY.

Am J Ophthalmol. 1999 Feb;127(2):137-41.PMID: 10030553 [PubMed - indexed for MEDLINE]Related articles